Cyns

Cyns is a biotechnology company focused on the discovery and development of novel therapeutics targeting cysteine metabolism and the ferroptosis pathway. Founded by pioneers in the field of ferroptosis, Scott Dixon and Brent Stockwell, the company leverages deep expertise in metabolic regulation to address unmet needs in oncology and neurodegenerative diseases. Cyns is backed by leading life science investors, including The Column Group, and is headquartered in San Francisco, California. The company's platform aims to modulate ferroptosis, a form of regulated cell death, to treat diseases where metabolic dysfunction plays a critical role.